title: [A Case of Pancreatic Cancer with Multiple Liver Metastases That Developed Postoperatively and Showed a Complete Response with S-1 Monotherapy].
abstract: We encountered a case of pancreatic cancer with multiple liver metastases that developed postoperatively and showed a complete response with S-1 monotherapy for a long time. A pancreaticoduodenectomy was successfully performed on an 80- year-old man. Multiple liver metastases developed 6 months postoperatively. Microscopically, the primary lesion was diagnosed as adenosquamous carcinoma with anaplastic carcinoma component, and the final diagnosis was considered to be Stage Ⅲ disease. S-1monotherapy (80 mg/day, administered for 4 weeks and then stopped for 2-weeks) was effective. A partial response was noted after 3 months, and 9 months after the initial administration of S-1, a complete response was achieved, which persisted for more than 12 months, according to contrast-enhanced CT evaluations.Serum CEA and CA19-9 levels, which became slightly elevated at the time of liver metastasis development, normalized promptly and remained within normal limits. Adverse effects of chemotherapy of more than grade 2 severity were not apparent, and the patient tolerated the 11th course of S-1 administration, consistently. A standard therapeutic strategy and its outcomes in cases of pancreatic cancer recurrence are not clearly outlined in the Japanese Guideline for the Treatment of Pancreatic Cancer. A case of pancreatic cancer with multiple liver metastases that developed postoperatively and showed a complete response with S-1 monotherapy is reported in this paper.
authors.affiliation: Dept. of Surgery, Itami City Hospital.
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Saso
authors.forename: Masaru
authors.initials: M
authors.lastname: Murata
authors.forename: Kensuke
authors.initials: K
authors.lastname: Asai
authors.forename: Moyuru
authors.initials: M
authors.lastname: Yamada
authors.forename: Tomoko
authors.initials: T
authors.lastname: Yagi
authors.forename: Shinsuke
authors.initials: S
authors.lastname: Katsuyama
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Sawami
authors.forename: Hidekazu
authors.initials: H
authors.lastname: Takahashi
authors.forename: Osamu
authors.initials: O
authors.lastname: Takayama
authors.forename: Nobuo
authors.initials: N
authors.lastname: Tanaka
authors.forename: Masashi
authors.initials: M
authors.lastname: Baba
authors.forename: Masayuki
authors.initials: M
authors.lastname: Yamamoto
authors.forename: Masahiro
authors.initials: M
authors.lastname: Hiratsuka
mesh_terms: D000369:Aged, 80 and over; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D004338:Drug Combinations; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D016577:Pancreaticoduodenectomy; D012074:Remission Induction; D005641:Tegafur / Q000627:therapeutic use*
chemical_list: D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid